Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non–small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance) Journal Article


Authors: Altorki, N.; Wang, X.; Damman, B.; Mentlick, J.; Landreneau, R.; Wigle, D.; Jones, D. R.; Conti, M.; Ashrafi, A. S.; Liberman, M.; de Perrot, M.; Mitchell, J. D.; Keenan, R.; Bauer, T.; Miller, D.; Stinchcombe, T. E.
Article Title: Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non–small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance)
Abstract: Background: We have recently reported the primary results of CALGB 140503 (Alliance), a randomized trial in patients with peripheral cT1aN0 non–small cell lung cancer (American Joint Committee on Cancer seventh) treated with either lobar resection (LR) or sublobar resection (SLR). Here we report differences in disease-free survival (DFS), overall survival (OS) and lung cancer–specific survival (LCSS) between LR, segmental resection (SR), and wedge resection (WR). We also report differences between WR and SR in terms of surgical margins, rate of locoregional recurrence (LRR), and expiratory flow rate at 6 months postoperatively. Methods: Between June 2007 and March 2017, a total of 697 patients were randomized to LR (n = 357) or SLR (n = 340) stratified by clinical tumor size, histology, and smoking history. Ten patients were converted from SLR to LR, and 5 patients were converted from LR to SLR. Survival endpoints were estimated using the Kaplan–Maier estimator and tested by the stratified log-rank test. The Kruskal–Wallis test was used to compare margins and changes in forced expiratory volume in 1 second (FEV1) between groups, and the χ2 test was used to test the associations between recurrence and groups. Results: A total of 362 patients had LR, 131 had SR, and 204 had WR. Basic demographic and clinical and pathologic characteristics were similar in the 3 groups. Five-year DFS was 64.7% after LR (95% confidence interval [CI], 59.6%-70.1%), 63.8% after SR (95% CI, 55.6%-73.2%), and 62.5% after WR (95% CI, 55.8%-69.9%) (P =.888, log-rank test). Five-year OS was 78.7% after LR, 81.9% after SR, and 79.7% after WR (P =.873, log-rank test). Five-year LCSS was 86.8% after LR, 89.2% after SR, and 89.7% after WR (P =.903, log-rank test). LRR occurred in 12% after SR and in 14% after WR (P =.295). At 6 months postoperatively, the median reduction in % FEV1 was 5% after WR and 3% after SR (P =.930). Conclusions: In this large randomized trial, LR, SR, and WR were associated with similar survival outcomes. Although LRR was numerically higher after WR compared to SR, the difference was not statistically significant. There was no significant difference in the reduction of FEV1 between the SR and WR groups. © 2023 The American Association for Thoracic Surgery
Keywords: cancer survival; controlled study; human tissue; aged; disease-free survival; major clinical study; overall survival; cancer recurrence; postoperative period; disease free survival; cancer staging; neoplasm staging; tumor volume; randomized controlled trial; carcinoma, non-small-cell lung; lung neoplasms; pneumonectomy; lung cancer; smoking; pathology; histology; lung tumor; phase 3 clinical trial; kaplan meier method; forced expiratory volume; randomized trial; lobectomy; flow rate; non small cell lung cancer; cumulative incidence; surgical margin; kaplan-meier estimate; wedge resection; procedures; sublobar resection; humans; human; male; female; article; segmentectomy; x-ray computed tomography; ecog performance status; expiratory flow rate
Journal Title: Journal of Thoracic and Cardiovascular Surgery
Volume: 167
Issue: 1
ISSN: 0022-5223
Publisher: Mosby Elsevier  
Date Published: 2024-01-01
Start Page: 338
End Page: 347.e1
Language: English
DOI: 10.1016/j.jtcvs.2023.07.008
PUBMED: 37473998
PROVIDER: scopus
PMCID: PMC10794519
DOI/URL:
Notes: Article -- Erratum issued, see DOI: 10.1016/j.jtcvs.2024.12.011 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Randolph Jones
    417 Jones